共 287 条
[1]
Eastell R(2006)Effect of an aromatase inhibitor on bmd and bone turnover markers: 2 year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230) J Bone Miner Res 21 1215-1223
[2]
Hannon RA(2007)Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study Lancet Oncol 8 119-127
[3]
Cuzick J(2005)Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17 J Natl Cancer Inst 97 1262-1271
[4]
Dowsett M(2007)Changes in bone turnover and in bone mass in women with breast cancer switched from tamoxifen to exemestane Bone 40 205-210
[5]
Clack G(2009)Effects of exemestane and tamoxifen on bone health within the Tamoxifen Exemestane Adjuvant Multicentre (TEAM) trial: results of a German, 12 month, prospective, randomised substudy Ann Oncol 20 1203-1209
[6]
Adams JE(2008)Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100 month analysis of the ATAC trial Lancet Oncol 9 45-53
[7]
Coleman RE(2016)Elevated incidence of fractures in women with invasive breast cancer Osteoporos Int 27 499-507
[8]
Banks LM(2015)Denosumab and fracture risk in women with breast cancer—author’s reply Lancet 386 2057-2058
[9]
Girgis SI(2011)Cancer therapy associated bone loss: implications for hip fractures in mid-life women with breast cancer Clin Cancer Res 17 560-568
[10]
Kilburn LS(2012)Fracture risk in women with breast cancer: a population-based study J Bone Miner Res 27 1196-1205